

**EVP R&D DR MITCHELL GLASS DISCUSS WITH BRR MEDIA DATA FROM THE
PHASE II CLINICAL TRIAL OF INV103 (ala-Cpn10) IN LUPUS PATIENTS**

Brisbane, Australia and Delaware, United States, 18 August 2015: Australian respiratory technology company Invion Limited (ASX: IVX) is delighted to invite investors to listen to Invion's Dr Mitchell Glass discuss the results of the Phase II clinical trial of INV103 (ala-Cpn10) in patients with systemic lupus (SLE).

In this audiocast, Dr Glass discusses:

- the results of the phase II clinical trial
- the significance of this data and completion of the study
- next steps for the program

To access the audiocast, please visit this link: <http://brrmedia.com/event/140108>

About Invion Limited

Invion is a life sciences company focussed on the development of treatments for major opportunities in respiratory disease and autoimmune disease. The Group has three drug assets in development, and three phase II clinical trials, regulated by the Food & Drug Administration (FDA), currently underway in the United States. INV102 (nadolol) a beta blocker (beta adrenergic inverse agonist) currently used to treat high blood pressure and migraine, is being repurposed to treat chronic inflammatory airway diseases, including asthma and chronic obstructive pulmonary disease (COPD). INV104 (zafirlukast) is a leukotriene receptor antagonist (LTRA) that reduces inflammation, constriction of the airways, and the build-up of mucus in the lungs. INV103 (ala-Cpn10) is a modified, naturally occurring human protein which has been proposed as a founding member of the Resolution Associated Molecular Pattern (RAMPs) family hypothesised to maintain and restore immune homeostasis. Invion is an ASX listed company (ASX:IVX), with its clinical headquarters in Delaware, USA.

FOR MORE INFORMATION CONTACT

Managing Director and CEO: Dr Greg Collier. P: 07 3295 0500 greg.collier@inviongroup.com